Saxenda vs Wegovy: Compare Differences & Prices

When comparing side effects between liraglutide (Saxenda) and semaglutide (Wegovy), it helps to understand that both medications belong to a group called GLP-1 receptor agonists and work in similar ways. Because of this, they can cause some of the same side effects, but each medication also has its own unique pattern of tolerability. The most common side effects with both drugs are mild and manageable for many people, especially as the body adjusts to the medication over time.

Gastrointestinal symptoms are the most frequent side effects reported for both liraglutide and semaglutide. These include nausea, vomiting, diarrhea, constipation, stomach pain, bloating, and indigestion. For example, in one clinical study, nausea occurred in about 59% of people taking liraglutide and 61% of people taking semaglutide. Constipation was reported in roughly 32% of users of liraglutide and 39% of semaglutide users, while diarrhea affected about 18% and 28% of people, respectively. Other digestive issues like burping and decreased appetite also occur, but with less frequency. These side effects are generally mild to moderate and tend to happen most often when starting the medication or after a dose increase. Many users find that these symptoms become less bothersome as their body gets used to the medicine.

Both medications can also cause headache, dizziness, and injection site reactions, though the likelihood varies. For instance, injection site reactions such as redness or irritation were seen in about 11% of people using liraglutide, but hardly at all with semaglutide in head-to-head studies. Fatigue, or feeling more tired than usual, was reported in about 11% with liraglutide and 10% with semaglutide. Mild side effects are typically short-lived, but if they persist or worsen, you should discuss this with your healthcare provider.

Though many side effects are manageable, both liraglutide and semaglutide come with warnings for more serious risks. These include:

• Gallbladder problems, such as gallstones or inflammation

• Pancreatitis, which is a sudden inflammation of the pancreas

• Kidney injury

• Low blood sugar, especially if used with other diabetes medicines

• Increased heart rate

• Serious allergic reactions, which may include swelling, rash, or difficulty breathing

• Depression or suicidal thoughts

Both drugs carry a boxed warning about a possible risk of thyroid cancer, based on findings in animal studies. While this risk has not been confirmed in people, your doctor will likely avoid prescribing either drug if you or a family member has had medullary thyroid cancer, or a rare condition called multiple endocrine neoplasia syndrome type 2. If you notice any swelling or a lump in your neck, hoarseness, difficulty swallowing, or shortness of breath while on either medication, contact your health provider right away.

Another important difference is in how often people stop using these medications because of side effects. In some studies, a higher percentage of people taking liraglutide discontinued treatment compared to those on semaglutide, often due to gastrointestinal symptoms or side effects like insomnia or gallbladder issues. However, the experience can be highly individual—some may tolerate one drug better than the other. Ultimately, if you develop side effects that are severe or don’t go away, you and your healthcare provider can discuss switching to another option or making adjustments to your treatment plan. Always follow your provider’s instructions and report any new or bothersome symptoms while on either medication.

Saxenda and Wegovy are both prescription medications designed to help with weight loss and long-term weight management. They are approved for use in similar groups of people, but there are some important differences in the specific conditions they are intended to treat. Understanding these differences can help you and your health care provider determine which medication may be more appropriate for your unique health needs.

Both Saxenda and Wegovy are approved for adults who have obesity, which means having a body mass index (BMI) of 30 or greater. They are also approved for adults who are overweight (BMI of 27 or greater) and have at least one weight-related health condition, such as high blood pressure, high cholesterol, or type 2 diabetes. These medications are meant to be used along with lifestyle changes, including a reduced-calorie diet and increased physical activity, to help achieve and maintain weight loss.

For younger people, both drugs are available for adolescents age 12 and older with obesity, but there is a key difference between them. Saxenda can be prescribed for adolescents who weigh more than 132 pounds (60 kg), while Wegovy does not have this minimum weight requirement in its approval. Instead, Wegovy is approved for adolescents age 12 or older who meet the clinical definition of obesity for their age and sex, without any specific minimum weight set. This makes Wegovy an option for a broader range of young people who have obesity, as it does not limit eligibility by weight.

Wegovy goes beyond weight loss by offering additional benefits for certain health conditions, expanding its potential uses. In adults who have heart disease and are either overweight or have obesity, Wegovy is approved to help reduce the risk of major cardiovascular events. This means it can lower the chance of heart attack, stroke, or cardiovascular death in people with existing heart disease who also carry extra weight. No such approval exists for Saxenda. In addition, Wegovy is also approved for the treatment of a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) in adults who have moderate to advanced liver scarring, in combination with dietary and exercise changes. Saxenda does not have approval for liver disease management.

Here is a summary comparing the conditions each medication treats:

• Both Saxenda and Wegovy are approved for:

  • Adults with obesity (BMI 30 or higher)

  • Adults with overweight (BMI 27 or higher) and at least one weight-related health condition

  • Adolescents ages 12 and older with obesity (Saxenda: requires weight over 132 pounds; Wegovy: no minimum weight)

• Only Wegovy is approved for:

  • Reducing the risk of major heart events in adults with established heart disease who have overweight or obesity

  • Treating metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis

This means that, while both medicines help people lose weight, Wegovy may be the preferred choice for those who are also seeking to improve heart health or manage specific liver problems connected to being overweight or obese. However, not everyone will be a candidate for both drugs, and individual factors such as age, current weight, other health conditions, and insurance coverage can affect which option is best. Only a health care professional can determine if either of these medications is safe and appropriate based on your overall health history and goals.